# Digestive Disease Week (DDW) 2023 Conflicts of Interest
List of conflicts of interest for **The Global Evolution of Inflammatory Bowel Disease across Four Epidemiologic Stages: A Systematic Review of Incidence and Prevalence Studies over the Past Century**.

**Joseph W. Windsor**: None declared.<br>
**Lindsay Hracs**: None declared.<br> 
**Julia Gorospe**: None declared.<br>
**Stephanie Coward**: None declared.<br>
**Michael Buie**: None declared.<br>
**Joshua Quan**: None declared.<br>
**Ante Markovinvić**: None declared.<br>
**Léa Caplan**: Has received a research grant from AbbVie.<br>
**Michael Cummings**: None declared.<br>
**Richard Gearry**: To be confirmed.<br>
**Paulo Kotze**: To be confirmed.<br>
**Maria T. Abreu**: To be confirmed.<br>
**David T. Rubin**: To be confirmed.<br>
**Iris Dotan**: To be confirmed.<br>
**Charles Bernstein**: Grant / Research support from: Unrestricted educational grants from AbbVie Canada, Janssen Canada, Pfizer Canada, Bristol Myers Squibb Canada, and Takeda Canada. Has received research grants from AbbVie Canada, Amgen Canada, Pfizer Canada, and Sandoz Canada and contract grants from Janssen, AbbVie and Pfizer, Consultant of: AbbVie Canada, Amgen Canada, Bristol Myers Squibb Canada, JAMP Pharmaceuticals, Janssen Canada, Pfizer Canada, Sandoz Canada, and Takeda. Speakers bureau of: AbbVie Canada, Janssen Canada, Pfizer Canada and Takeda Canada.<br>
**Remo Panaccione**: Consultant of: Abbott, AbbVie, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Fresenius Kabi, Genentech, Gilead Sciences, Glaxo- Smith Kline, JAMP Bio, Janssen, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pendopharm, Pfizer, Progenity, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity Therapeutics, Takeda Pharmaceuticals, Theravance Biopharma, Trellus, Viatris, UCB. Advisory Boards for: AbbVie, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Ferring, Fresenius Kabi, Genentech, Gilead Sciences, Glaxo-Smith Kline, JAMP Bio, Janssen, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Sandoz Shire, Sublimity Therapeutics, Takeda Pharmaceuticals, Speakers bureau of: AbbVie, Amgen, Arena Pharmaceuticals, Bristol-Myers Squibb, Celgene, Eli Lilly, Ferring, Fresenius Kabi, Gilead Sciences, Janssen, Merck, Organon, Pfizer, Roche, Sandoz, Shire, Takeda Pharmaceuticals.<br>
**Siew C. Ng**: To be confirmed.<br>
**Gilaad G. Kaplan**: Grant / Research support from: Ferring, Janssen, AbbVie, GlaxoSmith Kline, Merck, and Shire, Consultant of: Gilead, Speakers bureau of: AbbVie, Janssen, Pfizer, Amgen, and Takeda.
